Table 2 Factors associated with relapse during pregnancy in RA and spa patients
RA | SpA | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No relapse (n = 36) | Relapse (n = 17) | p | No relapse (n = 43) | Relapse (n = 28) | p | ||||||
N | n (%) or mean ± SD or median [25th; 75th percentiles] | N | n (%) or mean ± SD or median [25th; 75th percentiles] | N | n (%) or mean ± SD or median [25th; 75th percentiles] | N | n (%) or mean ± SD or median [25th; 75th percentiles] | ||||
Age at conception, years | 36 | 32.6 ± 5.1 | 17 | 32.8 ± 4.9 | 0.87 | 43 | 31.6 ± 4.1 | 28 | 32.0 ± 4.4 | 0.64 | |
Disease duration, years | 36 | 6 [4; 10] | 17 | 9 [2; 12] | 0.98 | 42 | 6 [4; 11] | 28 | 5 [2; 6] | 0.06 | |
Current smoking | 36 | 3 (8.3) | 17 | 2 (11.8) | 0.65 | 42 | 2 (4.8) | 28 | 1 (3.6) | 1.00 | |
Current alcohol consumption | 36 | 1 (2.8) | 17 | 0 (0.0) | 1.00 | 42 | 1 (2.4) | 28 | 0 (0.0) | 1.00 | |
Body mass index, kg/m² | 20 | 25.3 ± 6.8 | 12 | 22.9 ± 3.3 | 0.30 | 22 | 25.1 ± 4.6 | 19 | 24.7 ± 4.4 | 0.74 | |
Nulliparity | 36 | 17 (47.2) | 16 | 13 (81.3) | 0.02 | 43 | 21 (48.8) | 28 | 13 (46.4) | 0.84 | |
Rheumatoid factor positive | 34 | 27 (79.4) | 17 | 12 (70.6) | 0.50 | − | − | − | − | − | |
ACPA positive | 35 | 24 (68.6) | 17 | 13 (76.5) | 0.75 | − | − | − | − | − | |
Erosion | 35 | 19 (54.3) | 17 | 5 (29.4) | 0.09 | − | − | − | − | − | |
HLA-B27 positive | − | − | − | − | − | 43 | 25 (58.1) | 28 | 15 (53.6) | 0.70 | |
SpA clinical manifestation | 0.94 | ||||||||||
Axial | − | − | − | − | − | 42 | 21 (50.0) | 28 | 15 (53.6) | ||
Peripheral | − | − | − | − | − | 42 | 9 (21.4) | 28 | 6 (21.4) | ||
Both | − | − | − | − | − | 42 | 12 (28.6) | 28 | 7 (25.0) | ||
X-ray or RMI sacroiliitis | − | − | − | − | − | 43 | 23 (53.5) | 28 | 21 (75.0) | 0.07 | |
History of corticosteroid use | 36 | 29 (80.6) | 17 | 13 (76.5) | 0.73 | 43 | 17 (38.5) | 28 | 8 (28.6) | 0.35 | |
History of csDMARDs use | 36 | 32 (88.9) | 17 | 13 (76.5) | 0.25 | 43 | 17 (39.5) | 28 | 9 (32.1) | 0.53 | |
Methotrexate | 36 | 27 (75.0) | 17 | 13 (76.5) | 1.00 | 43 | 11 (25.6) | 28 | 7 (25.0) | 0.96 | |
Other | 36 | 12 (33.3) | 17 | 5 (29.4) | 0.78 | 43 | 12 (27.9) | 28 | 6 (21.4) | 0.54 | |
History of NSAIDs use | 36 | 16 (44.4) | 17 | 12 (70.6) | 0.08 | 43 | 33 (76.7) | 28 | 17 (60.7) | 0.15 | |
History of bDMARDs use | 36 | 16 (44.4) | 17 | 12 (70.6) | 0.08 | 43 | 31 (72.1) | 28 | 26 (92.9) | 0.03 | |
Disease flare last 12 months before conception | 30 | 7 (23.3) | 13 | 8 (61.5) | 0.03 | 22 | 21 (95.5) | 14 | 14 (100) | 1.00 | |
Disease activity | |||||||||||
DAS28-CRP | 26 | 2.2 ± 1.1 | 14 | 3.3 ± 1.3 | 0.008 | − | − | − | − | − | |
DAS28-CRP-3 | 26 | 2.2 ± 0.9 | 14 | 3.0 ± 1.1 | 0.02 | − | − | − | − | − | |
VAS global activity patient, /10 | 32 | 1 [0; 3] | 16 | 4 [2; 7] | 0.005 | 34 | 3 [1; 6] | 22 | 2 [1; 6] | 0.93 | |
VAS global activity practitioner, /10 | 29 | 1 [0; 2] | 11 | 4 [1; 5] | 0.02 | 32 | 3 [0; 5] | 19 | 2 [0; 4] | 0.98 | |
BASDAI | − | − | − | − | − | 35 | 3.2 ± 2.2 | 24 | 2.8 ± 2.0 | 0.66 | |
ASDAS-CRP | − | − | − | − | − | 21 | 2.1 ± 1.2 | 16 | 1.7 ± 1.2 | 0.41 | |
CRP, mg/L | 28 | 3 [1; 8] | 14 | 4 [1; 13] | 0.38 | 27 | 3 [2; 8] | 23 | 3 [1; 13] | 0.98 | |
Tender joint count* | 31 | 0 [0; 1] | 17 | 1 [0; 4] | 0.04 | 37 | 0 [0; 0] | 25 | 0 [0; 0] | 0.75 | |
Swollen joint count* | 32 | 0 [0; 0] | 17 | 1 [0; 3] | 0.02 | 37 | 0 [0; 0] | 25 | 0 [0; 0] | 0.64 | |